Ceres Brain Therapeutics is a biotechnology company advancing CBT101, a novel central nervous system (CNS) therapeutic candidate that has recently progressed into Phase 2 clinical development. CBT101 is positioned to address major unmet needs in severe neurological diseases through a differentiated, indication specific approach to neuronal energy dysfunction.

CBT101 is being developed in amyotrophic lateral sclerosis (ALS), a rapidly progressive and fatal neurodegenerative disease with limited treatment options, as well as in creatine transporter deficiency (CTD), a rare paediatric neurological disorder with no effective disease modifying therapies. While based on a single molecular entity, CBT101 applies distinct mechanistic rationales aligned with each indication: targeting neuronal and mitochondrial energy dysfunction in ALS, and restoring intracellular creatine availability in neurons in CTD.

The program is supported by robust non clinical data and early clinical evidence demonstrating central nervous system activity and target engagement in humans. CBT101 is delivered as a non invasive nasal spray, offering a clear advantage in terms of patient convenience and treatment burden compared with injectable or hospital based therapies.

To support ongoing Phase 2 development and pipeline expansion, Ceres Brain Therapeutics is currently seeking to raise USD 20 million and is actively exploring strategic partnership opportunities, including co‑development, licensing, and regional collaborations, to accelerate development and maximize the value of CBT101 across its neurological indications.